Clinical Trials Directory

Trials / Completed

CompletedNCT03522181

Glucose-insulin-potassium Therapy Improves Lactic Acidosis in Liver Transplantation

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
80 (actual)
Sponsor
Central South University · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Lactic acidosis is a common phenomenon occurring during orthotopic liver transplantation (OLT), especially during the anhepatic and early postreperfusion phases. However, little drugs effectively decrease the degree of lactic acidosis when it happens. The aim of this study is to explore whether glucose-Insulin-Potassium(GIK) infusion can relieve metabolic acidosis and improve perioperative outcome in patients undergoing OLT.

Detailed description

Intraoperative metabolic acidosis begins soon after graft reperfusion and persists for several days. The current standard treatment for severe acidosis during OLT is NaHCO3, although it may compromise myocardial performance, exacerbate lactic acid accumulation and cause central nervous system demyelination. Surgical procedure is a primary source of endogenous lactic acid production, especially visceral ischemia originating from anhepatic stage. The present study thus hypothesized that GIK solution may improve metabolic acidosis in OLT patients through its unique effects of metabolic alleviation. Patients for orthotopic liver transplantation was enrolled and received either GIK or placebo. GIK or placebo infusion started after anesthesia induction. Intraoperative measures were mean arterial pressure, HR, arterial blood gases, lactate, glucose, Na, liver and renal function indexes. Outcome measures were time to tracheal extubation, intensive care unit, length of stay, complications, hospital length of stay, requirement for postoperative plasma transfusion, retransplantation, and perioperative mortality.

Conditions

Interventions

TypeNameDescription
OTHERsalinesaline
OTHERInsulin

Timeline

Start date
2016-02-01
Primary completion
2017-10-01
Completion
2017-11-01
First posted
2018-05-11
Last updated
2018-05-11

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03522181. Inclusion in this directory is not an endorsement.